Chi Sheng Pharma & Biotech Co., Ltd.(TW:4111)
NT$28.500.00 (0.00%)
TW:4111
Chi Sheng Pharma & Biotech Co., Ltd. financials statements
NT$28.50
At close:0.00 (0.00%)
Chi Sheng Pharma & Biotech Co., Ltd. (4111) Ratios
Chi Sheng Pharma & Biotech Co., Ltd. Ratios
TW:4111's free cash flow for Q2 2026 was NT$58.84M. For the 2026 fiscal year, TW:4111's free cash flow was decreased by NT$-32.49M and operating cash flow was NT$91.33M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.01 | 2.10 | 1.78 | 1.78 | 1.46 |
| Quick Ratio | 1.78 | 1.84 | 1.58 | 1.57 | 1.26 |
| Cash Ratio | 0.96 | 0.90 | 0.84 | 0.95 | 0.56 |
| Solvency Ratio | 0.42 | 0.37 | 0.24 | 0.39 | 0.29 |
| Operating Cash Flow Ratio | 0.89 | 0.57 | 0.17 | 0.45 | 0.31 |
| Short-Term Operating Cash Flow Coverage | 11.73 | 1.26 | 0.62 | 0.76 | 1.07 |
| Net Current Asset Value | NT$ 368.07M | NT$ 309.54M | NT$ 256.96M | NT$ 279.25M | NT$ 92.43M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.11 | 0.07 | 0.16 | 0.18 |
| Debt-to-Equity Ratio | 0.04 | 0.15 | 0.10 | 0.24 | 0.27 |
| Debt-to-Capital Ratio | 0.03 | 0.13 | 0.09 | 0.19 | 0.21 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.40 | 1.37 | 1.45 | 1.47 | 1.51 |
| Debt Service Coverage Ratio | 6.48 | 1.04 | 1.09 | 0.89 | 1.43 |
| Interest Coverage Ratio | 385.50 | 56.77 | 41.93 | 107.41 | 121.57 |
| Debt to Market Cap | 0.02 | 0.11 | 0.08 | 0.19 | 0.10 |
| Interest Debt Per Share | 0.82 | 3.29 | 2.19 | 5.12 | 5.15 |
| Net Debt to EBITDA | -1.45 | -0.73 | -1.71 | -0.70 | 0.19 |
| Profitability Margins | |||||
| Gross Profit Margin | 36.88% | 34.08% | 32.34% | 36.96% | 34.88% |
| EBIT Margin | 14.48% | 11.96% | 8.37% | 14.33% | 13.00% |
| EBITDA Margin | 19.74% | 17.55% | 14.21% | 20.71% | 20.73% |
| Operating Profit Margin | 14.48% | 8.49% | 5.77% | 14.33% | 13.00% |
| Pretax Profit Margin | 15.02% | 11.82% | 8.23% | 14.20% | 12.89% |
| Net Profit Margin | 11.93% | 9.49% | 6.47% | 13.47% | 7.90% |
| Continuous Operations Profit Margin | 11.93% | 9.49% | 6.47% | 15.68% | 10.53% |
| Net Income Per EBT | 79.44% | 80.34% | 78.64% | 94.90% | 61.28% |
| EBT Per EBIT | 103.76% | 139.17% | 142.67% | 99.07% | 99.18% |
| Return on Assets (ROA) | 8.48% | 6.32% | 3.89% | 8.55% | 4.87% |
| Return on Equity (ROE) | 11.90% | 8.68% | 5.63% | 12.60% | 7.34% |
| Return on Capital Employed (ROCE) | 13.50% | 7.19% | 4.66% | 12.42% | 10.95% |
| Return on Invested Capital (ROIC) | 10.42% | 5.11% | 3.35% | 10.19% | 8.05% |
| Return on Tangible Assets | 8.48% | 6.33% | 3.89% | 8.56% | 4.87% |
| Earnings Yield | 9.32% | 7.33% | 4.81% | 10.47% | 6.44% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.84 | 3.56 | 3.43 | 4.03 | 3.62 |
| Payables Turnover | 4.38 | 9.49 | 3.17 | 9.60 | 11.57 |
| Inventory Turnover | 8.40 | 7.93 | 8.05 | 7.28 | 7.38 |
| Fixed Asset Turnover | 1.77 | 1.53 | 1.44 | 1.44 | 1.13 |
| Asset Turnover | 0.71 | 0.67 | 0.60 | 0.63 | 0.62 |
| Working Capital Turnover Ratio | 3.14 | 3.05 | 2.91 | 3.94 | 3.43 |
| Cash Conversion Cycle | 55.05 | 110.06 | 36.81 | 102.61 | 118.69 |
| Days of Sales Outstanding | 95.03 | 102.51 | 106.56 | 90.46 | 100.76 |
| Days of Inventory Outstanding | 43.43 | 46.01 | 45.35 | 50.16 | 49.48 |
| Days of Payables Outstanding | 83.40 | 38.46 | 115.10 | 38.01 | 31.55 |
| Operating Cycle | 138.46 | 148.52 | 151.90 | 140.62 | 150.24 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 6.84 | 3.74 | 1.31 | 3.77 | 2.45 |
| Free Cash Flow Per Share | 5.27 | 2.25 | -0.48 | 1.91 | -2.21 |
| Dividend Paid and CapEx Coverage Ratio | 2.71 | 1.50 | 0.44 | 1.32 | 0.43 |
| Capital Expenditure Coverage Ratio | 4.36 | 2.50 | 0.73 | 2.03 | 0.52 |
| Operating Cash Flow Coverage Ratio | 8.39 | 1.15 | 0.61 | 0.74 | 0.48 |
| Operating Cash Flow to Sales Ratio | 0.30 | 0.18 | 0.07 | 0.19 | 0.14 |
| Free Cash Flow Yield | 17.89% | 8.48% | -1.89% | 7.41% | -10.07% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 10.71 | 13.65 | 20.78 | 9.56 | 15.49 |
| Price-to-Sales (P/S) Ratio | 1.28 | 1.29 | 1.34 | 1.29 | 1.23 |
| Price-to-Book (P/B) Ratio | 1.28 | 1.18 | 1.17 | 1.20 | 1.14 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 5.59 | 11.79 | -52.89 | 13.49 | -9.94 |
| Price-to-Operating Cash Flow Ratio | 4.31 | 7.08 | 19.15 | 6.85 | 9.00 |
| Price-to-Earnings Growth (PEG) Ratio | 0.26 | 0.23 | -0.38 | 0.11 | 0.42 |
| Enterprise Value Multiple | 5.03 | 6.64 | 7.75 | 5.51 | 6.10 |
| Enterprise Value | 1.37B | 1.36B | 1.17B | 1.30B | 1.29B |
| EV to EBITDA | 5.03 | 6.64 | 7.75 | 5.51 | 6.10 |
| EV to Sales | 0.99 | 1.17 | 1.10 | 1.14 | 1.27 |
| EV to Free Cash Flow | 4.34 | 10.62 | -43.32 | 11.97 | -10.25 |
| EV to Operating Cash Flow | 3.34 | 6.37 | 15.68 | 6.07 | 9.28 |
| Tangible Book Value Per Share | 23.05 | 22.34 | 21.45 | 21.43 | 19.30 |
| Shareholders’ Equity Per Share | 23.08 | 22.37 | 21.48 | 21.45 | 19.32 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.21 | 0.20 | 0.21 | -0.10 | 0.18 |
| Revenue Per Share | 23.01 | 20.45 | 18.69 | 20.06 | 17.94 |
| Net Income Per Share | 2.75 | 1.94 | 1.21 | 2.70 | 1.42 |
| Tax Burden | 0.79 | 0.80 | 0.79 | 0.95 | 0.61 |
| Interest Burden | 1.04 | 0.99 | 0.98 | 0.99 | 0.99 |
| Research & Development to Revenue | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 |
| SG&A to Revenue | 0.21 | 0.24 | 0.25 | 0.22 | 0.21 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 2.49 | 1.55 | 1.09 | 1.57 | 1.33 |
Currency in TWD
